Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kazia Therapeutics ( (KZIA) ) has shared an update.
On May 22, 2025, Kazia Therapeutics Limited held its Annual General Meeting, where shareholders voted on the re-election of Robert Apple as a director. The resolution was approved with a significant majority, reflecting shareholder confidence in the company’s leadership. This decision is expected to support Kazia’s ongoing strategic initiatives and strengthen its position in the biotechnology sector.
The most recent analyst rating on (KZIA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a company operating in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is headquartered in Sydney, Australia, and is committed to advancing treatments for challenging forms of cancer.
Average Trading Volume: 42,457
Technical Sentiment Signal: Sell
Current Market Cap: $4.18M
For a thorough assessment of KZIA stock, go to TipRanks’ Stock Analysis page.